# US Orphan Drugs Market

> US Orphan Drugs Market Research Report: Size, Share, Trend Analysis By Drug Type (Biologics, Non-Biologics), By Sale (Generics, Prescribed), By Drug (Revlimid, Rituxan, Opdivo, Keytruda, Imbruvica, Soliris, Jakaf, Pomalyst, Darzalex, Spinraza, Adcetris) and By Therapy Class (Oncology, Blood, Central Nervous Systems, Endocrine, Cardiovascular, Respiratory) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 9.08%
- **2024:** $ 53.59 Billion
- **2025:** $ 58.46 Billion
- **2035:** $ 139.43 Billion
- **Key Players:** Vertex Pharmaceuticals (US), Biogen (US), Amgen (US), Sanofi (FR), Novartis (CH), Roche (CH), Regeneron Pharmaceuticals (US), Sobi (SE), Eisai (JP)

**Report ID:** MRFR/Pharma/11599-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** July 20, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-orphan-drugs-market-13124

---

## Market Summary

## **US Orphan Drugs Market Overview**

**As per MRFR analysis, the US Orphan Drugs Market Size was estimated at 49.13 (USD Billion) in 2023. The US Orphan Drugs Market Industry is expected to grow from 53.59(USD Billion) in 2024 to 143 (USD Billion) by 2035. The US Orphan Drugs Market CAGR (growth rate) is expected to be around 9.333% during the forecast period (2025 - 2035).**

### **Key US Orphan Drugs Market Trends Highlighted**

The US Orphan Drugs Market is experiencing significant trends driven by various factors, particularly the increasing demand for treatments of rare diseases. One of the key market drivers is the favorable regulatory environment established by the FDA through initiatives like the Orphan Drug Act. This act incentivizes pharmaceutical companies to develop therapies for rare conditions by offering benefits such as tax credits and a seven-year period of market exclusivity. Additionally, the growing prevalence of genetic disorders and the rising awareness surrounding rare diseases are propelling the need for orphan drugs.

There is also an increase in collaborations between biotech firms and large pharmaceutical companies that aim to leverage resources effectively in developing treatments for niche patient populations.Opportunities to be explored in the US Orphan Drugs Market include advancements in technology and innovation in drug development processes. The advent of gene therapy and personalized medicine is opening doors to new treatments which cater specifically to the genetic profiles of patients. Furthermore, there is potential for expanding the pipeline of [orphan drugs](../../../reports/orphan-drugs-market-2312) targeting additional rare diseases, thus addressing unmet medical needs.

Recent trends show an uptick in investments directed toward orphan drug development, underpinned by venture capital and public funding aimed at supporting research in rare diseases. The increasing participation of biopharmaceutical companies in orphan drug development is fostering growth and competition in the market.Moreover, patient advocacy groups are becoming more influential, advocating for access to treatments and driving demand, which will keep the focus on developing innovative solutions in the US Orphan Drugs Market. Overall, as the landscape evolves, key stakeholders are positioned to meet the growing healthcare needs of rare disease patients in the United States.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Orphan Drugs Market Drivers**

### **Increasing Prevalence of Rare Diseases**

The United States has witnessed a notable increase in the prevalence of rare diseases, which is a key driver for the US Orphan Drugs Market Industry. According to the United States National Institutes of Health, approximately 7,000 rare diseases affect 30 million Americans, highlighting the critical need for targeted therapies.

This surge creates significant demand for orphan drugs, particularly as the FDA designates many of these conditions as orphan diseases that require specialized treatments.The involvement of major pharmaceutical companies like Vertex Pharmaceuticals and Biogen in developing therapies for conditions such as cystic fibrosis and spinal muscular atrophy exemplifies the industry's commitment to addressing these unmet medical needs. Moreover, advancements in genomics and bioinformatics are accelerating drug discovery processes for rare diseases, contributing to market growth.

### **Supportive Regulatory Framework**

The supportive regulatory framework in the United States, characterized by the Orphan Drug Act of 1983, plays a pivotal role in encouraging the development of orphan drugs. This legislation provides incentives such as tax credits, grants for Clinical Research, and extended market exclusivity to pharmaceutical manufacturers. In fiscal year 2021, the FDA reported a record number of orphan drug designations, further showcasing regulatory support for the US Orphan Drugs Market Industry.This framework not only promotes innovation but also ensures that patients with rare diseases gain timely access to vital therapeutics, bolstering investor interest and fostering a dynamic market environment.

### **Rising Investment in Research and Development**

The US Orphan Drugs Market Industry is significantly fueled by rising investment in Research and Development (R&D), particularly for rare diseases. Pharmaceutical companies are increasingly channeling funds into R&D efforts for rare conditions, with investment in rare disease therapeutics expected to reach billions annually.

The Pharmaceutical Research and Manufacturers of America reported that companies invested over USD 83 billion in R&D in 2020, a trend expected to continue as they seek to develop innovative orphan drugs.This commitment not only enhances treatment options for patients but also drives overall market growth and attracts collaborations with biotechnology firms for knowledge exchange and resources.

## **US Orphan Drugs Market Segment Insights**

### **Orphan Drugs Market Drug Type Insights**

The Drug Type segment of the US Orphan Drugs Market is an essential component that highlights the distinction between Biologics and Non-Biologics, each playing a crucial role in the treatment of rare diseases. Biologics, which include vaccines, blood components, and gene therapies, have gained considerable importance due to their ability to target specific biological pathways, thus improving treatment outcomes for patients with complex disorders. This segment not only demonstrates robust growth but also fosters innovations that are often backed by extensive Research and Development initiatives, significantly impacting the overall market landscape.

On the other hand, Non-Biologics comprise small molecule drugs, which have been traditional players in the orphan drugs space. They are formulated from chemical compounds and tend to exhibit lower production costs compared to their biologic counterparts, making them a cost-effective solution for treating various rare diseases. The presence of both Biologics and Non-Biologics creates a diversified treatment arsenal that caters to the unique needs of patients in the US, contributing to the dynamic nature of the orphan drug market.

Government support through incentives such as tax credits and exclusive marketing rights has resulted in increased interest in developing drugs within both categories, enhancing their respective roles in addressing unmet medical needs. This evolving landscape is characterized by strategic collaborations between pharmaceutical companies and research institutions to advance drug development for rare diseases, furthering both segments' importance in providing effective and lasting treatment solutions.

By focusing on these two distinct drug types, the US Orphan Drugs Market positioning emphasizes the need for tailored therapeutic approaches, ensuring a comprehensive response to the challenges faced by patients who have limited treatment options. This adaptability and focus not only underscore the significance of each drug type but also signal a promising future for the market as it progresses toward fulfilling the therapeutic demands of a diverse patient population.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Orphan Drugs Market Sale Insights**

The US Orphan Drugs Market demonstrates significant growth and opportunity, with the Sale segment being a key component of this expansion. The overall market is expected to reach a valuation of 53.59 billion USD by 2024, illustrating the strong demand for specialized treatments for rare diseases. Within this context, the Sale segment can be divided into Generics and Prescribed medications, each playing a vital role in addressing unmet medical needs. Generics contribute to affordability and accessibility for patients, enabling more widespread use of essential medications for rare conditions.

On the other hand, Prescribed drugs represent advanced therapies that focus on targeted treatment options, driving innovation in the industry. The increasing prevalence of rare diseases and the ongoing emphasis on Research and Development within the pharmaceutical sector fuel the growth of these segments. Moreover, favorable regulatory environments, coupled with the orphan drug designation benefits, enhance market dynamics in the US effectively. The challenges of high development costs and the need for robust distribution strategies continue to shape the landscape, while opportunities for collaborative partnerships and breakthrough therapies pave the way for future advancements in the US Orphan Drugs Market.

### **Orphan Drugs Market Drug Insights**

The US Orphan Drugs Market predominantly revolves around the Drug segment, which caters to rare diseases impacting a small population yet holds substantial importance for patient care. Among these, Revlimid has been recognized for its effectiveness in treating multiple myeloma, establishing itself as a critical treatment option. Rituxan's role in addressing various malignancies, including lymphomas, underscores the significance of targeted therapies in the orphan drug space. Opdivo and Keytruda have revolutionized immunotherapy for certain cancers, offering innovative solutions where traditional treatments may fall short.

Imbruvica demonstrates the potential for personalized medicine in managing chronic lymphocytic leukemia, illustrating the growing trend toward tailored therapeutic approaches. Furthermore, Soliris is pivotal in the treatment of conditions like paroxysmal nocturnal hemoglobinuria, signifying the need for effective therapies in life-threatening blood disorders. Jakaf and Pomalyst have shown promise for patients with myelofibrosis and multiple myeloma respectively, addressing unmet medical needs effectively.

Darzalex, with its novel mechanism, aids in multiple myeloma management, while Spinraza represents a breakthrough in spinal muscular atrophy treatment.Lastly, Adcetris provides a targeted therapy for specific lymphomas, signaling a shift towards precision medicine. Collectively, these drugs illustrate the dynamic landscape of the US Orphan Drugs Market, emphasizing both the need for continued innovation and the critical importance of these treatments in enhancing patient outcomes.

### **Orphan Drugs Market Therapy Class Insights**

The US Orphan Drugs Market, particularly within the Therapy Class segment, has shown substantial potential and growth. In recent years, regulatory incentives have driven significant interest and investment in this sector. Oncology therapies lead the market, driven by a rising prevalence of rare cancers and ongoing Research and Development efforts, making it a vital area for innovation. Blood disorders also represent a crucial part of the market as advancements in gene therapies and biologics have provided new treatment avenues for patients with rare blood conditions.

The Central Nervous System category is essential too, targeting rare neurological disorders that require specialized therapies, reflecting a growing recognition of the need for effective solutions in this area. The Endocrine therapies, addressing rare endocrine disorders, have gained traction due to increased awareness and improved diagnostic tools. Cardiovascular orphan drugs have started garnering attention as they cater to niche markets with unmet needs, while the Respiratory sector sees a push for treatments aimed at rare lung diseases.

Collectively, these Therapy Class segments contribute to the US Orphan Drugs Market revenue by addressing diverse and challenging health conditions, thereby offering both substantial opportunities and challenges for stakeholders looking to engage in this growing industry.As the market continues to evolve, robust regulatory frameworks and advancements in technology are expected to bolster the development of effective orphan therapies across these areas.

## **US Orphan Drugs Market Key Players and Competitive Insights**

The US Orphan Drugs Market is characterized by its rapid growth trajectory, driven by the increasing prevalence of rare diseases and a supportive regulatory environment. This market, catering to a niche segment, presents unique competitive dynamics as pharmaceutical companies strive to develop and market drugs specifically designed for conditions affecting small patient populations. The opportunities within this market are bolstered by the Orphan Drug Act, which provides incentives such as tax breaks, extended exclusivity periods, and expedited FDA approval for drugs that cater to rare diseases, thereby attracting both established pharmaceutical giants and smaller biotech firms looking to innovate.

Given the complexity and high costs associated with the development of orphan drugs, companies are focused on strategic collaborations, mergers, and acquisitions to boost their portfolios and enhance their market position, which significantly shapes the competitive landscape.Genzyme holds a prominent position in the US Orphan Drugs Market, recognized for its commitment to addressing rare diseases through innovative therapeutic solutions. The company has successfully positioned itself by investing heavily in research and development, leading to a robust pipeline of orphan drug candidates that address unmet medical needs.

Genzyme's strength lies in its established relationships with healthcare providers and patient advocacy groups, which facilitate access to treatments for rare diseases. Furthermore, the company's reputation for delivering high-quality products has earned it the trust of both healthcare professionals and patients alike, allowing it to maintain a significant market share in the US. By building partnerships and leveraging its expertise, Genzyme continues to enhance its presence and influence in this specialized market.BristolMyers Squibb is also a notable player in the US Orphan Drugs Market, with a strong portfolio of key products designed to treat rare conditions.

The company has made significant strides in expanding its presence in this sector through strategic mergers and acquisitions that have bolstered its rare disease offerings. BristolMyers Squibb’s strengths include a diverse range of therapies in its pipeline, particularly in oncology and hematology, which cater to underserved patient populations. The company emphasizes innovation and has a strong commitment to research, enabling it to bring cutting-edge therapies to market. The presence of well-established distribution channels and a strong sales force further enhances its ability to reach healthcare providers effectively.

By focusing on improving patient outcomes and investing in collaborative initiatives, BristolMyers Squibb continues to solidify its role in the US Orphan Drugs Market.

### **Key Companies in the US Orphan Drugs Market Include**

## **US Orphan Drugs Market Industry Developments**

The US Orphan Drugs Market has experienced significant developments recently, marked by a robust growth trajectory. In July 2023, Regeneron Pharmaceuticals announced positive results for its orphan drug candidate, aimed at treating rare genetic disorders, indicating increasing investments in innovative therapies. Meanwhile, in August 2023, Horizon Therapeutics received FDA approval for a new orphan drug targeting an uncommon form of thyroid disease, further demonstrating the trend of expanding treatment options. Notably, Genzyme and Gilead Sciences report notable increases in market valuation, reflecting heightened demand for specialized medicines.

Recent mergers have also shaped the landscape; in November 2022, Amgen completed its acquisition of Horizon Therapeutics, enhancing its portfolio in the orphan drug sector. Furthermore, in March 2023, AbbVie announced its acquisition of a promising orphan drug candidate from a biotech firm, signaling aggressive expansion strategies evident among key market players. Overall, the US Orphan Drugs Market continues to evolve, driven by growing investments, innovative drug approvals, and strategic mergers, highlighting its critical role in addressing unmet medical needs for rare diseases.

## **US Orphan Drugs Market Segmentation Insights**

### **Orphan Drugs Market Drug Type Outlook**

- Biologics
- Non-Biologics

### **Orphan Drugs Market Sale Outlook**

- Generics
- Prescribed

### **Orphan Drugs Market Drug Outlook**

- Revlimid
- Rituxan
- Opdivo
- Keytruda
- Imbruvica
- Soliris
- Jakaf
- Pomalyst
- Darzalex
- Spinraza
- Adcetris

### **Orphan Drugs Market Therapy Class Outlook**

- Oncology
- Blood
- Central Nervous Systems
- Endocrine
- Cardiovascular
- Respiratory

## Market Drivers

### Growing Patient Advocacy Groups

The orphan drugs market is increasingly influenced by the emergence of patient advocacy groups in the US. These organizations play a crucial role in raising awareness about rare diseases and advocating for the development of effective treatments. They often collaborate with pharmaceutical companies to facilitate clinical trials and provide valuable insights into patient needs. The presence of these groups has been linked to a 25% increase in the number of orphan drug applications submitted to the FDA over the past five years. Their efforts not only enhance the visibility of rare diseases but also foster a supportive environment for innovation in the orphan drugs market. As patient voices become more prominent, the demand for tailored therapies is expected to rise, further propelling market growth.

### Increasing Prevalence of Rare Diseases

The orphan drugs market is experiencing growth due to the rising prevalence of rare diseases in the US. It is estimated that approximately 7,000 rare diseases affect around 30 million individuals in the country. This growing patient population creates a substantial demand for effective treatments, thereby driving the orphan drugs market. As more diseases are identified and classified as rare, pharmaceutical companies are increasingly motivated to develop targeted therapies. The orphan drugs market is projected to reach $200 billion by 2026, reflecting a compound annual growth rate (CAGR) of 10% from 2021 to 2026. This trend indicates a robust market potential, as stakeholders recognize the need for innovative solutions to address unmet medical needs.

### Enhanced Research and Development Funding

In the US, the orphan drugs market benefits from increased funding for research and development (R&D) initiatives. Government programs and private investments are focusing on rare diseases, leading to a surge in clinical trials and innovative therapies. The National Institutes of Health (NIH) has allocated significant resources to support research in this area, with funding exceeding $1 billion annually for rare diseases. This financial backing encourages pharmaceutical companies to invest in the orphan drugs market, as the potential for successful drug development becomes more viable. Furthermore, the Orphan Drug Act provides incentives such as tax credits and extended market exclusivity, which further stimulate R&D efforts. As a result, the market is likely to see a continuous influx of novel therapies aimed at rare conditions.

### Regulatory Framework and Fast-Track Approvals

The orphan drugs market is significantly shaped by the regulatory framework in the US, particularly the FDA's commitment to expediting the approval process for orphan drugs. The Orphan Drug Act provides various incentives, including fast-track designations and priority review, which can reduce the time to market for new therapies. This regulatory support has led to a notable increase in the number of orphan drugs approved, with over 400 new therapies receiving FDA approval in the last decade. The streamlined approval process not only encourages pharmaceutical companies to invest in the orphan drugs market but also ensures that patients gain timely access to essential treatments. As regulatory bodies continue to prioritize rare diseases, the market is likely to expand further.

### Technological Innovations in Drug Development

The orphan drugs market is benefiting from technological innovations that enhance drug development processes. Advances in genomics, bioinformatics, and personalized medicine are enabling researchers to identify potential therapeutic targets more efficiently. For instance, the use of CRISPR technology and other gene-editing tools has shown promise in developing treatments for genetic disorders. The market is projected to grow as these technologies become more integrated into the drug development pipeline. It is estimated that the adoption of innovative technologies could reduce development costs by up to 30%, making it more feasible for companies to pursue orphan drug development. As a result, the orphan drugs market is likely to see an influx of novel therapies that address previously untreatable conditions.

## Future Outlook

The [Orphan Drugs Market](https://www.marketresearchfuture.com/reports/orphan-drugs-market-2312) is projected to grow at a 9.08% CAGR from 2025 to 2035, driven by increased R&D investments, regulatory incentives, and rising patient demand.

**New opportunities:**

- Development of personalized gene therapies for rare diseases. Expansion of telehealth services for remote patient monitoring. Strategic partnerships with biotech firms for innovative drug development.

By 2035, the orphan drugs market is expected to achieve substantial growth, driven by innovation and strategic collaborations.

## Segment Insights

### By Indication: Neurological Disorders (Largest) vs. Genetic Disorders (Fastest-Growing)

In the US orphan drugs market, Neurological Disorders represent the largest segment, driven by a significant patient population and high unmet medical needs. This segment is characterized by various conditions, including rare diseases such as Huntington's and ALS, requiring specialized treatments that cater to these unique patient requirements. In contrast, Genetic Disorders, while smaller in overall share, are quickly gaining traction due to advancements in gene therapies and a growing understanding of genetic conditions, particularly in the pediatric population. 

The growth trends in the US orphan drugs market indicate that the Genetic Disorders segment is on a robust upward trajectory, fueled by increasing investments in research and development, along with favorable regulatory conditions for gene therapies. The growing prevalence of rare genetic conditions is leading to higher demand for targeted treatments. Additionally, collaborations between pharmaceutical companies and biotech firms are fostering innovation in this area, making Genetic Disorders a focal point for future growth in the orphan drugs sector.

Neurological Disorders: Dominant vs. Genetic Disorders: Emerging

Neurological Disorders are established as a dominant force in the orphan drugs market due to their extensive applicability across various rare diseases, showcasing significant treatment advancements over recent years. This segment thrives on a unique combination of a large, diagnosed patient population and the innovation surrounding orphan drug development, which has led to numerous FDA approvals for effective therapies. On the other hand, Genetic Disorders represent an emerging area with considerable potential as recent breakthroughs in gene editing and therapy provide new avenues for treatment. The increasing identification of genetic conditions and the rapid approval processes for innovative therapies are propelling the interest and investments in this sector, ultimately leading to a promising outlook for the Genetic Disorders segment.

### By Drug Type: Approved Drugs (Largest) vs. Pipeline Drugs (Fastest-Growing)

In the US orphan drugs market, the distribution of market share among the drug types reveals that Approved Drugs dominate the segment, being well-established with a significant presence. On the other hand, Pipeline Drugs are emerging and represent a crucial part of the market growth strategy as pharmaceutical companies invest heavily in research and development to bring innovative treatments to patients in need.

The growth trends for these segments are driven by increasing investments in rare disease research and the growing recognition of the need for effective orphan therapies. Approved Drugs continue to maintain their stronghold due to regulatory incentives and established patient populations. Conversely, Pipeline Drugs are gaining momentum, benefiting from advancements in biotechnology and a surge in clinical trials, indicating a promising future for new entrants in the orphan drug space.

Approved Drugs (Dominant) vs. Pipeline Drugs (Emerging)

Approved Drugs play a dominant role in the US orphan drugs market as they are often backed by extensive clinical data and favorable regulatory conditions, leading to their widespread use. They are suitable for treating a variety of rare diseases, which has garnered the trust of healthcare providers and patients alike. In contrast, Pipeline Drugs, while currently less influential, present significant potential as they undergo various stages of clinical development. These emerging drugs are tailored to address unmet medical needs and benefit from growing funding and support, positioning them as critical players for the future of orphan treatments.

### By Route of Administration: Injectable (Largest) vs. Oral (Fastest-Growing)

In the US orphan drugs market, the route of administration segment reveals a diverse landscape of options. Injectable therapies dominate this segment, capturing the largest share of the market due to their effectiveness and the ability to ensure proper dosage. Oral administration follows, appealing to patients seeking convenience, though it currently holds a smaller segment of the market. Other routes, such as intravenous and topical, continue to serve niche needs but are less prevalent overall.

Looking ahead, growth trends indicate a strategic shift towards particularly oral routes, which are expected to expand rapidly as patient adherence increases along with the demand for more convenient treatment options. Innovation in drug formulation and delivery methods for injectables will sustain their dominance, while the rising prevalence of chronic diseases drives interest in both oral and intravenous routes, highlighting the dynamic nature of the US orphan drugs market.

Injectable: Dominant vs. Oral: Emerging

Injectable administration occupies a dominant position in the US orphan drugs market, primarily due to its direct delivery methods which facilitate rapid therapeutic responses, especially for serious conditions. This route accounts for a significant portion of treatment options for orphan diseases requiring precise dosing and immediate effects. Conversely, oral administration is emerging as a highly favorable alternative, particularly as advancements in formulations make oral drugs more effective and patient-friendly. An increasing number of patients prefer oral medications due to their ease of use and improved compliance, driving a competitive landscape where both routes are vital. The battle for market share between injectables and oral therapies underscores the evolving demands and preferences within this specialized field.

### By Distribution Channel: Specialty Pharmacy (Largest) vs. Online Pharmacy (Fastest-Growing)

In the US orphan drugs market, the distribution share is predominantly led by Specialty Pharmacy, which has established its critical role in providing medications that require special handling and patient care. Retail Pharmacy and Hospital Pharmacy also hold significant shares, but their growth has been comparatively slower, making it essential for stakeholders to focus on the evolving landscape of distribution channels.

The growth trends indicate a remarkable increase in Online Pharmacy, primarily driven by the rise in digital healthcare solutions and consumer preferences towards convenience. This shift is further accelerated by advancements in technology that streamline the process of acquiring orphan drugs. In contrast, Specialty Pharmacies continue to innovate their services, cementing their position as the dominant player in this market segment.

Specialty Pharmacy (Dominant) vs. Online Pharmacy (Emerging)

Specialty Pharmacy has become the dominant distribution channel for orphan drugs, offering specialized services tailored to the unique needs of patients requiring these medications. These pharmacies focus on complex therapies and provide additional support such as patient education, adherence programs, and care coordination. Their ability to manage high-cost therapies and work closely with healthcare providers ensures that patients receive optimal care, reinforcing their strong market position. On the other hand, Online Pharmacy is emerging as a key player, appealing to the tech-savvy consumer base that values accessibility and convenience. This channel is rapidly growing due to the increasing adoption of e-commerce in pharmaceuticals, allowing patients to order medications from the comfort of their homes, thus reshaping the distribution dynamics.

## Competitive Benchmarking

The orphan drugs market is characterized by a dynamic competitive landscape, driven by the increasing prevalence of rare diseases and the growing demand for innovative therapies. Key players such as Vertex Pharmaceuticals (US), Biogen (US), and Amgen (US) are strategically positioned to leverage their research capabilities and established market presence. Vertex Pharmaceuticals (US) focuses on developing transformative therapies for cystic fibrosis, while Biogen (US) emphasizes its commitment to neurological disorders, particularly in rare conditions. Amgen (US) is diversifying its portfolio through targeted therapies, indicating a collective shift towards specialized treatment options that cater to niche patient populations.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness. The market appears moderately fragmented, with a mix of established players and emerging biotech firms. This structure allows for a competitive interplay where larger companies can influence market dynamics through strategic partnerships and acquisitions, while smaller firms contribute innovative solutions that challenge the status quo.
In October Vertex Pharmaceuticals (US) announced a collaboration with a leading gene therapy company to explore novel treatment avenues for rare genetic disorders. This partnership is likely to enhance Vertex's research capabilities and expand its therapeutic offerings, positioning the company favorably in a rapidly evolving market. The strategic importance of this collaboration lies in its potential to accelerate the development of groundbreaking therapies, thereby reinforcing Vertex's leadership in the orphan drugs sector.
In September Biogen (US) launched a new initiative aimed at increasing access to its therapies for rare neurological diseases. This initiative includes partnerships with healthcare providers and patient advocacy groups, which may significantly improve patient outcomes and adherence to treatment regimens. By focusing on access and support, Biogen is not only enhancing its market presence but also addressing critical gaps in the healthcare system for rare disease patients.
In August Amgen (US) completed the acquisition of a biotech firm specializing in rare disease treatments, which is expected to bolster its pipeline and enhance its competitive edge. This acquisition reflects a broader trend of consolidation within the orphan drugs market, where larger firms seek to integrate innovative solutions and expand their therapeutic reach. The strategic importance of this move lies in Amgen's ability to leverage the acquired company's expertise and technologies to accelerate the development of new therapies.
As of November current trends in the orphan drugs market include a pronounced focus on digitalization, sustainability, and the integration of artificial intelligence in drug development processes. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise to tackle complex challenges. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a model centered on innovation, technological advancement, and supply chain reliability. This shift underscores the importance of agility and responsiveness in meeting the needs of patients with rare diseases.

## Recent News & Developments

The US Orphan Drugs Market has experienced significant developments recently, marked by a robust growth trajectory. In July 2023, Regeneron Pharmaceuticals announced positive results for its orphan drug candidate, aimed at treating rare genetic disorders, indicating increasing investments in innovative therapies. Meanwhile, in August 2023, Horizon Therapeutics received FDA approval for a new orphan drug targeting an uncommon form of thyroid disease, further demonstrating the trend of expanding treatment options. Notably, Genzyme and Gilead Sciences report notable increases in market valuation, reflecting heightened demand for specialized medicines.

Recent mergers have also shaped the landscape; in November 2022, Amgen completed its acquisition of Horizon Therapeutics, enhancing its portfolio in the orphan drug sector. Furthermore, in March 2023, AbbVie announced its acquisition of a promising orphan drug candidate from a biotech firm, signaling aggressive expansion strategies evident among key market players. Overall, the US Orphan Drugs Market continues to evolve, driven by growing investments, innovative drug approvals, and strategic mergers, highlighting its critical role in addressing unmet medical needs for rare diseases.

## Report Scope

| MARKET SIZE 2024 | 53.59(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 58.46(USD Billion) |
| MARKET SIZE 2035 | 139.43(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.08% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Vertex Pharmaceuticals (US), Biogen (US), Amgen (US), Sanofi (FR), Novartis (CH), Roche (CH), Regeneron Pharmaceuticals (US), Sobi (SE), Eisai (JP) |
| Segments Covered | Indication, Drug Type, Route of Administration, Distribution Channel |
| Key Market Opportunities | Advancements in gene therapy and personalized medicine enhance potential in the orphan drugs market. |
| Key Market Dynamics | Rising regulatory support enhances innovation and competition in the orphan drugs market, driving therapeutic advancements. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the market valuation of the US orphan drugs market in 2024?**
A: The market valuation of the US orphan drugs market was $53.59 Billion in 2024.

**Q: What is the projected market valuation for the US orphan drugs market by 2035?**
A: The projected market valuation for the US orphan drugs market is $139.43 Billion by 2035.

**Q: What is the expected CAGR for the US orphan drugs market during the forecast period 2025 - 2035?**
A: The expected CAGR for the US orphan drugs market during the forecast period 2025 - 2035 is 9.08%.

**Q: Which segments are included in the US orphan drugs market, and what were their valuations in 2024?**
A: The segments include Neurological Disorders ($5.36 Billion), Genetic Disorders ($8.07 Billion), Oncological Disorders ($15.67 Billion), Metabolic Disorders ($10.71 Billion), and Infectious Diseases ($14.78 Billion) in 2024.

**Q: What are the key players in the US orphan drugs market?**
A: Key players in the US orphan drugs market include Vertex Pharmaceuticals, Biogen, Amgen, Sanofi, Novartis, Roche, Regeneron Pharmaceuticals, Sobi, and Eisai.

**Q: What was the valuation of approved drugs in the US orphan drugs market in 2024?**
A: The valuation of approved drugs in the US orphan drugs market was $20.0 Billion in 2024.

**Q: How much is the pipeline drugs segment valued at in the US orphan drugs market as of 2024?**
A: The pipeline drugs segment was valued at $25.0 Billion in the US orphan drugs market in 2024.

**Q: What is the valuation of injectable drugs in the US orphan drugs market as of 2024?**
A: The valuation of injectable drugs in the US orphan drugs market was $20.0 Billion in 2024.

**Q: What distribution channels are present in the US orphan drugs market, and what were their valuations in 2024?**
A: Distribution channels include Hospital Pharmacy ($20.0 Billion), Retail Pharmacy ($15.0 Billion), Online Pharmacy ($8.0 Billion), and Specialty Pharmacy ($10.59 Billion) in 2024.

**Q: What is the projected growth for the oncological disorders segment in the US orphan drugs market by 2035?**
A: The oncological disorders segment is projected to grow to $40.66 Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-orphan-drugs-market-13124*